FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2002302492> ?p ?o ?g. }

• W2002302492 endingPage "1773" @default.
• W2002302492 startingPage "1763" @default.
• W2002302492 abstract "IntroductionNon-small cell lung cancer (NSCLC) is often diagnosed in advanced stages and is associated with poor outcomes. Existing standards of care for NSCLC result in low overall cure rates, suggesting that novel treatment approaches are needed. In this review, we provide an updated look at the clinical data on immunotherapeutic interventions, which potentiate the immune system's response to lung tumor cells.MethodsWe searched articles on PubMed and abstracts from recent oncology meetings for publications on immunotherapies with clinical applicability to the treatment of NSCLC.ResultsResults from phase 2 trials show vaccine therapies, which target either tumor cells themselves or aberrantly expressed tumor markers (mucin 1, melanoma-associated antigen 3, or epidermal growth factor), may be promising immunotherapeutics for NSCLC. Antigen-independent immunotherapies, such as anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibodies, talactoferrin alfa, and toll-like receptor 9 agonists, act on a stimulated immune system regardless of the tumor antigen and may be feasible interventions for metastatic NSCLC. Several immunotherapies are undergoing phase 3 studies to assess optimal treatment settings and to determine clinical benefit compared with current standard treatments for NSCLC.ConclusionsA growing body of evidence suggests that immune responses to lung tumors are present. Immunotherapeutic interventions, including vaccine therapy and antigen-independent immunomodulatory strategies, may improve outcomes in NSCLC. Furthermore, treatments that enhance antitumor immune responses may prove to be synergistic with chemotherapy. Identification of biomarkers and further elucidation of immunotherapeutic mechanisms of action will be essential in determining which patients will experience the greatest benefit from immunotherapy. Non-small cell lung cancer (NSCLC) is often diagnosed in advanced stages and is associated with poor outcomes. Existing standards of care for NSCLC result in low overall cure rates, suggesting that novel treatment approaches are needed. In this review, we provide an updated look at the clinical data on immunotherapeutic interventions, which potentiate the immune system's response to lung tumor cells. We searched articles on PubMed and abstracts from recent oncology meetings for publications on immunotherapies with clinical applicability to the treatment of NSCLC. Results from phase 2 trials show vaccine therapies, which target either tumor cells themselves or aberrantly expressed tumor markers (mucin 1, melanoma-associated antigen 3, or epidermal growth factor), may be promising immunotherapeutics for NSCLC. Antigen-independent immunotherapies, such as anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibodies, talactoferrin alfa, and toll-like receptor 9 agonists, act on a stimulated immune system regardless of the tumor antigen and may be feasible interventions for metastatic NSCLC. Several immunotherapies are undergoing phase 3 studies to assess optimal treatment settings and to determine clinical benefit compared with current standard treatments for NSCLC. A growing body of evidence suggests that immune responses to lung tumors are present. Immunotherapeutic interventions, including vaccine therapy and antigen-independent immunomodulatory strategies, may improve outcomes in NSCLC. Furthermore, treatments that enhance antitumor immune responses may prove to be synergistic with chemotherapy. Identification of biomarkers and further elucidation of immunotherapeutic mechanisms of action will be essential in determining which patients will experience the greatest benefit from immunotherapy." @default.
• W2002302492 created "2016-06-24" @default.
• W2002302492 creator A5066167770 @default.
• W2002302492 creator A5075347427 @default.
• W2002302492 creator A5077579849 @default.
• W2002302492 date "2011-10-01" @default.
• W2002302492 modified "2023-10-11" @default.
• W2002302492 title "Immunotherapy for Non-small Cell Lung Cancer: Novel Approaches to Improve Patient Outcome" @default.
• W2002302492 cites W1513110975 @default.
• W2002302492 cites W1853976744 @default.
• W2002302492 cites W1964056896 @default.
• W2002302492 cites W1974892500 @default.
• W2002302492 cites W1980484335 @default.
• W2002302492 cites W1993615391 @default.
• W2002302492 cites W1998681197 @default.
• W2002302492 cites W2001498331 @default.
• W2002302492 cites W2003427916 @default.
• W2002302492 cites W2004841304 @default.
• W2002302492 cites W2006358054 @default.
• W2002302492 cites W2010244581 @default.
• W2002302492 cites W2018217352 @default.
• W2002302492 cites W2026187161 @default.
• W2002302492 cites W2029744149 @default.
• W2002302492 cites W2030177319 @default.
• W2002302492 cites W2043836056 @default.
• W2002302492 cites W2046609236 @default.
• W2002302492 cites W2047127667 @default.
• W2002302492 cites W2053829861 @default.
• W2002302492 cites W2055175265 @default.
• W2002302492 cites W2056998032 @default.
• W2002302492 cites W2069157431 @default.
• W2002302492 cites W2069372863 @default.
• W2002302492 cites W2071589683 @default.
• W2002302492 cites W2071793654 @default.
• W2002302492 cites W2072073440 @default.
• W2002302492 cites W2075808338 @default.
• W2002302492 cites W2080091291 @default.
• W2002302492 cites W2089220120 @default.
• W2002302492 cites W2097995306 @default.
• W2002302492 cites W2100158834 @default.
• W2002302492 cites W2100912832 @default.
• W2002302492 cites W2103959341 @default.
• W2002302492 cites W2108348820 @default.
• W2002302492 cites W2110252240 @default.
• W2002302492 cites W2112621029 @default.
• W2002302492 cites W2114300639 @default.
• W2002302492 cites W2115330744 @default.
• W2002302492 cites W2115786482 @default.
• W2002302492 cites W2116058268 @default.
• W2002302492 cites W2119366998 @default.
• W2002302492 cites W2123694113 @default.
• W2002302492 cites W2124430059 @default.
• W2002302492 cites W2125208575 @default.
• W2002302492 cites W2128973831 @default.
• W2002302492 cites W2130155727 @default.
• W2002302492 cites W2132157071 @default.
• W2002302492 cites W2134594413 @default.
• W2002302492 cites W2140111836 @default.
• W2002302492 cites W2145835533 @default.
• W2002302492 cites W2146236962 @default.
• W2002302492 cites W2147996829 @default.
• W2002302492 cites W2148586726 @default.
• W2002302492 cites W2156763707 @default.
• W2002302492 cites W2158734599 @default.
• W2002302492 cites W2164374194 @default.
• W2002302492 cites W2165181124 @default.
• W2002302492 cites W2166084034 @default.
• W2002302492 cites W2168278891 @default.
• W2002302492 cites W2168340462 @default.
• W2002302492 cites W2168479321 @default.
• W2002302492 cites W2169300860 @default.
• W2002302492 cites W2236214911 @default.
• W2002302492 doi "https://doi.org/10.1097/jto.0b013e31822e28fc" @default.
• W2002302492 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21876456" @default.
• W2002302492 hasPublicationYear "2011" @default.
• W2002302492 type Work @default.
• W2002302492 sameAs 2002302492 @default.
• W2002302492 citedByCount "63" @default.
• W2002302492 countsByYear W20023024922012 @default.
• W2002302492 countsByYear W20023024922013 @default.
• W2002302492 countsByYear W20023024922014 @default.
• W2002302492 countsByYear W20023024922015 @default.
• W2002302492 countsByYear W20023024922016 @default.
• W2002302492 countsByYear W20023024922017 @default.
• W2002302492 countsByYear W20023024922018 @default.
• W2002302492 countsByYear W20023024922019 @default.
• W2002302492 countsByYear W20023024922022 @default.
• W2002302492 countsByYear W20023024922023 @default.
• W2002302492 crossrefType "journal-article" @default.
• W2002302492 hasAuthorship W2002302492A5066167770 @default.
• W2002302492 hasAuthorship W2002302492A5075347427 @default.
• W2002302492 hasAuthorship W2002302492A5077579849 @default.
• W2002302492 hasBestOaLocation W20023024921 @default.
• W2002302492 hasConcept C126322002 @default.
• W2002302492 hasConcept C143998085 @default.
• W2002302492 hasConcept C147483822 @default.
• W2002302492 hasConcept C203014093 @default.
• W2002302492 hasConcept C2776256026 @default.

• next